Characterization of dynamic changes in tumor-infiltrating lymphocytes (TIL) after neoadjuvant administration of CUE-101, an HPV16 E7-HLA-IL2 fusion protein, to patients with HPV+ locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
Jesse M. Zaretsky(Washington University in St. Louis), Sidharth V. Puram(Washington University in St. Louis), Nikhil Ram-Mohan(Stanford University), Anthony J. Apicelli(Washington University in St. Louis), R. Alex Harbison(Washington University in St. Louis), Matteo Levisetti, Patrik Pipkorn(Washington University in St. Louis), Riley Mullins(Washington University in St. Louis), Anish Suri(Bristol-Myers Squibb (United States)), Michael J. Moravan(Duke Medical Center), Jennifer F. De Los Santos(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Wade L. Thorstad(Washington University in St. Louis), Thomas F. Barrett(Washington University in St. Louis), Emily Stoller(University of Massachusetts Chan Medical School), Jessica Ley(Washington University in St. Louis), Steven N. Quayle(CTI BioPharma (Italy)), Ryan S. Jackson(Washington University in St. Louis)
Cited by 0
Related Papers
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k